Jagsonpal reports Q3 & 9MFY26 unaudited results with 6% revenue growth, 12.5% PAT growth, and cash balance of ₹1,757 Mn; management expects continued upside from ongoing initiatives.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.